77.5 B+
NAD+
Also known as: Nicotinamide adenine dinucleotide, NAD
Strong Clinical Evidence Research Chemical
Research Evidence 90.0/100
Safety Profile 65.0/100
119 Clinical Trials
Unknown: 19 PHASE4: 7 PHASE3: 18 PHASE2, PHASE3: 1 PHASE2: 18 PHASE1, PHASE2: 7 PHASE1: 6 NA: 41 EARLY_PHASE1: 2
- ROTEM Interpretation AI vs Experts Unknown Phase NOT_YET_RECRUITING Masarykova Nemocnice v Usti nad Labem, Krajska Zdravotni a.s.
- The New Third Generation Video Laryngeal Mask Evaluation Unknown Phase COMPLETED Masarykova Nemocnice v Usti nad Labem, Krajska Zdravotni a.s.
- The Exploratory Study on the Baseline Level of NAD+/NADH in Peripheral Blood Samples of Different Gender and Age Groups of Healthy Adults. Unknown Phase UNKNOWN Shanghai Cell Therapy Group Co.,Ltd
- PROCO Neck: The Course and Neuroplasticity in Neck Pain-Associated Disorders and Whiplash-Associated Disorders Unknown Phase NOT_YET_RECRUITING University of applied sciences
- SARS-CoV-2 Nucleic Acid Detection Kit Clinical Performance Study Unknown Phase COMPLETED TransGen Biotech Co., LTD
Showing 5 of 119 trials.
20 Research Papers
- CRISPR/Cas9-Mediated Knockout of the NAD-Dependent Lactate Dehydrogenases for Altered Stereospecific Lactic Acid Production in Lacticaseibacillus paracasei NC4. Biochem Genet unknown
- Zn(2+)-Dependent Modulation of the Mitochondrial Ca(2+) Uniporter Underlies Resveratrol-Mediated Protection against Myocardial Ischemia-Reperfusion Injury. Exp Cell Res unknown
- Sirt1 deficiency promotes dynamic fibroblast-to-myofibroblast transition in ligamentum flavum hypertrophy via the Smad2/3 pathway. Exp Cell Res unknown
- Alpha-ketoglutarate accelerates granulocyte-monocyte progenitor differentiation and atherosclerotic plaque inflammation via oxoglutarate receptor 1. Redox Biol unknown
- Copper supports regulatory T cell energetic state to sustain peripheral immune tolerance. Sci Immunol unknown
Showing 5 of 20 papers by citation count.
FDA Data
Not FDA-Approved
NAD+ has not been evaluated by the FDA for safety or efficacy. It is not approved for human therapeutic use in the United States.
Frequently Asked Questions
Is NAD+ FDA approved?
No, NAD+ has not been approved by the FDA for human therapeutic use. It is sold as a research chemical.
How many clinical trials has NAD+ been studied in?
NAD+ has been studied in 119 registered clinical trials. CheckPeptides tracks phase, status, and sponsor data for each trial.
What is the trust score for NAD+?
NAD+ has a CheckPeptides trust score of 77.5/100 (grade: B+). This score is based on clinical trial volume, research paper quality, FDA data, and evidence classification.
Last verified: April 8, 2026
Quick Facts
- Classification
- Coenzyme / metabolic cofactor
- Molecular Weight
- 663.4 Da
- PubChem
- CID 5892 ↗
- Regulatory Status
- N/A
Score Breakdown
Research Evidence 90.0/100
Safety Profile 65.0/100
Evidence Summary
- Clinical Trials
- 119
- Research Papers
- 20
- Trust Score
- 77.5/100
- Grade
- B+